Back to top
more

Actinium Pharmaceuticals (ATNM)

(Delayed Data from AMEX)

$8.73 USD

8.73
196,224

-0.17 (-1.91%)

Updated May 10, 2024 04:00 PM ET

After-Market: $8.72 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ATNM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Actinium Pharmaceuticals, Inc. [ATNM]

Reports for Purchase

Showing records 41 - 60 ( 91 total )

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 41

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ATNM

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 42

09/15/2021

Daily Note

Pages: 5

SIERRA Fully Enrolled, Endgame Set for Mid-''22; Next Data Update Expected at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 43

08/03/2021

Company Report

Pages: 7

2Q21 Results; Pivotal SIERRA Data in 1H22; More Actimab Data This Year; Target Adjusted to $45

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 44

04/01/2021

Company Report

Pages: 8

2020 Results; All About SIERRA; Target Adjusted to $57

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 45

03/12/2021

Company Report

Pages: 8

Actinium''s Approach Gets Impressive Nod; SIERRA Phase 3 Data Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 46

01/20/2021

Daily Note

Pages: 33

Biotech Should Keep the Wind at its Back in 2021; Top Healthcare Picks

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 47

01/13/2021

Daily Note

Pages: 5

Astellas Broadens its Investment into Actinium''s AWE Platform; SIERRA Data Mid-2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 48

12/29/2020

Company Report

Pages: 7

SIERRA Endgame Now Set; We See Blue Skies; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 49

12/08/2020

Daily Note

Pages: 8

Actimab-A Visibility Continues to Increase as We Await SIERRA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 50

12/07/2020

Company Report

Pages: 10

Actimab-A + CLAG-M Impresses at ASH as SIERRA Awaits its Pivotal Moment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 51

11/12/2020

Company Report

Pages: 7

KOL Assessments Provide a Sneak Peak of What''s to Come at ASH

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 52

11/04/2020

Daily Note

Pages: 5

Not an Abstract Placeholder Here; Actimab-A+CLAG ASH Abstract Impresses

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 53

10/28/2020

Company Report

Pages: 7

3Q20 Results; Things About to Get Real Exciting; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 54

10/23/2020

Company Report

Pages: 7

Iomab-ACT Combination With CAR-Ts Makes Sense; A Closer Look While Waiting for SIERRA

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 55

10/21/2020

Daily Note

Pages: 5

Following the Paths That Make Sense; NIH Links up Actinium With MSKCC

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 56

09/23/2020

Daily Note

Pages: 5

Pipeline Visibility Increasing as We Await SIERRA; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 57

08/17/2020

Company Report

Pages: 6

Critical Time Approaching Quickly; SIERRA Ad Hoc Exercised; PT Adjusted to $65 Post Reverse Split

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 58

06/04/2020

Company Report

Pages: 38

We are initiating coverage with a Buy rating and $3 price target.

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 59

06/07/2019

Company Report

Pages: 4

We are dropping coverage of ATNM shares due to the departure of the covering analyst.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 60

12/04/2018

Company Report

Pages: 4

Bullish on Phase 3 Update

Provider: Roth Capital Partners, Inc.

Analyst: MARANGO J

Price: 10.00

Research Provided by a Third Party